This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Citing articles on ISI (79)  • Contact me when this article is cited  Related Content  • Related letters  • Similar articles in JAMA  Topic Collections  • Evidence-Based Medicine  • Surgical Interventions  • Cardiovascular/ Cardiothoracic Surgery  • Review  • Cardiovascular Disease/ Myocardial Infarction  • Cardiovascular Intervention  • Revascularization  • Alert me on articles by topic

A Meta-analysis

Gilles Montalescot, MD, PhD; Maria Borentain, MD; Laurent Payot, MD; Jean Philippe Collet, MD, PhD; Daniel Thomas, MD

JAMA. 2004;292:362-366.

Context  Glycoprotein IIb/IIIa (Gp IIb/IIIa) inhibitors improve myocardial reperfusion and clinical outcomes of patients undergoing primary percutaneous coronary intervention (PCI), but optimal timing of administration remains unclear. No systematic reviews have comprehensively examined the effects of early vs delayed administration of these agents.

Objective  To perform a meta-analysis of randomized trials of early (prior to transfer to the catheterization laboratory) vs late (at the time of PCI) intravenous administration of Gp IIb/IIIa inhibitors in acute ST-segment elevation myocardial infarction (STEMI).

Data Sources  MEDLINE and the Cochrane Controlled Trials Register search of the literature over the past 10 years; papers presented at major cardiac conferences; consultation with national and international colleagues as well as Gp IIb/IIIa inhibitor drug manufacturers; and text and journal article bibliographies.

Study Selection and Data Extraction  We examined trials of randomized comparisons between early administration at the point of initial contact (emergency department or ambulance) and late administration (catheterization laboratory) of Gp IIb/IIIa inhibitors in STEMI. Outcome data had to be available on both culprit artery patency evaluated by Thrombolysis in Myocardial Infarction (TIMI) flow grades on admission and mortality. Two authors independently reviewed abstracts or complete articles. Six studies met inclusion criteria. Independent data extraction was performed by 2 reviewers and confirmed by consensus.

Data Synthesis  The 6 trials enrolled 931 STEMI patients treated with abciximab (3 trials) or tirofiban (3 trials) in combination with primary PCI. TIMI grade 2 or 3 flow (41.7% [194/465 vs 29.8% [139/466]) as well as TIMI grade 3 flow (20.3% [84/413] vs 12.2% [51/418]) were significantly more frequent in the early group compared with the late group (odds ratio [OR], 1.69; 95% confidence interval [CI], 1.28-2.22; P<.001; and OR, 1.85; 95% CI, 1.26-2.71; P<.001, respectively). The early administration of Gp IIb/IIIa inhibitors was associated with a 28% reduction of mortality from 4.7% to 3.4%, which was not significant but consistent with similar trends for reinfarction and the composite ischemic end point.

Conclusions  In a meta-analysis of 6 randomized trials, early administration of Gp IIb/IIIa inhibitors in STEMI appeared to improve coronary patency with favorable trends for clinical outcomes. These findings are supportive of a strategy of facilitated PCI. Further evaluations in adequately powered large trials are awaited to confirm the clinical benefit of this strategy.

Author Affiliations: Institut de Cardiologie, Pitié-Salpêtrière University Hospital, Paris, France.

RELATED LETTERS

Glycoprotein IIb/IIIa Inhibition
Heather Horton
JAMA. 2004;292(18):2211.
EXTRACT | FULL TEXT  

Glycoprotein IIb/IIIa Inhibition
Joel Klein
JAMA. 2004;292(18):2211.
EXTRACT | FULL TEXT  

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

The challenge of reducing time to reperfusion in patients with acute ST elevation myocardial infarction
van 't Hof
Eur Heart J 2008;29:1793-1794.
FULL TEXT  

Facilitated PCI in Patients with ST-Elevation Myocardial Infarction
Ellis et al.
NEJM 2008;358:2205-2217.
ABSTRACT | FULL TEXT  

Antithrombotic Therapy to Support Primary PCI
Morrow
NEJM 2008;358:2280-2282.
FULL TEXT  

The relative safety and efficacy of abciximab and eptifibatide in patients undergoing primary percutaneous coronary intervention insights from a large regional registry of contemporary percutaneous coronary intervention.
Gurm et al.
J Am Coll Cardiol 2008;51:529-535.
ABSTRACT | FULL TEXT  

The safety and efficacy of glycoprotein IIb/IIIa inhibitors for primary angioplasty: more options to choose and more time to decide.
Moliterno and Ziada
J Am Coll Cardiol 2008;51:536-537.
FULL TEXT  

Primary Percutaneous Coronary Intervention
Kapoor et al.
NEJM 2008;358:431-433.
FULL TEXT  

Antiplatelet therapy in percutaneous coronary intervention
Bode and Huber
Eur Heart J Suppl 2008;10:A13-A20.
ABSTRACT | FULL TEXT  

Transfer with GP IIb/IIIa inhibitor tirofiban for primary percutaneous coronary intervention vs. on-site thrombolysis in patients with ST-elevation myocardial infarction (STEMI): a randomized open-label study for patients admitted to community hospitals
Dobrzycki et al.
Eur Heart J 2007;28:2438-2448.
ABSTRACT | FULL TEXT  

Facilitated percutaneous coronary intervention: current concepts, promises, and pitfalls
Kiernan et al.
Eur Heart J 2007;28:1545-1553.
ABSTRACT | FULL TEXT  

Randomized Early Versus Late Abciximab in Acute Myocardial Infarction Treated With Primary Coronary Intervention (RELAx-AMI Trial)
Maioli et al.
J Am Coll Cardiol 2007;49:1517-1524.
ABSTRACT | FULL TEXT  

Abciximab in primary coronary stenting of ST-elevation myocardial infarction: a European meta-analysis on individual patients' data with long-term follow-up
Montalescot et al.
Eur Heart J 2007;28:443-449.
ABSTRACT | FULL TEXT  

Narrative review: reperfusion strategies for ST-segment elevation myocardial infarction.
Ting et al.
ANN INTERN MED 2006;145:610-617.
ABSTRACT | FULL TEXT  

Percutaneous Coronary Intervention After Fibrinolysis: A Multiple Meta-Analyses Approach According to the Type of Strategy
Collet et al.
J Am Coll Cardiol 2006;48:1326-1335.
ABSTRACT | FULL TEXT  

Three-year duration of benefit from abciximab in patient receiving stents for acute myocardial infarction in the randomized double-blind ADMIRAL study: reply
Montalescot
Eur Heart J 2006;27:1509-1509.
FULL TEXT  

Reperfusion Therapy Starts in the Ambulance
Verheugt
Circulation 2006;113:2377-2379.
FULL TEXT  

Implementation of Guidelines Improves the Standard of Care: The Viennese Registry on Reperfusion Strategies in ST-Elevation Myocardial Infarction (Vienna STEMI Registry)
Kalla et al.
Circulation 2006;113:2398-2405.
ABSTRACT | FULL TEXT  

Abciximab in Patients With Acute Coronary Syndromes Undergoing Percutaneous Coronary Intervention After Clopidogrel Pretreatment: The ISAR-REACT 2 Randomized Trial
Kastrati et al.
JAMA 2006;295:1531-1538.
ABSTRACT | FULL TEXT  

Implementation of reperfusion therapy in acute myocardial infarction. A policy statement from the European Society of Cardiology
Bassand et al.
Eur Heart J 2005;26:2733-2741.
ABSTRACT | FULL TEXT  

The role of glycoprotein IIb/IIIa inhibitors in primary percutaneous coronary intervention for ST elevation myocardial infarction
Svilaas et al.
Eur Heart J 2005;26:2479-2481.
FULL TEXT  

Three-year duration of benefit from abciximab in patients receiving stents for acute myocardial infarction in the randomized double-blind ADMIRAL study
The ADMIRAL Investigators
Eur Heart J 2005;26:2520-2523.
ABSTRACT | FULL TEXT  

Facilitated percutaneous coronary intervention
Brodie
Heart 2005;91:1527-1529.
FULL TEXT  

Should primary angioplasty be available for all patients with an ST elevation myocardial infarction?
de Belder
Heart 2005;91:1509-1511.
ABSTRACT | FULL TEXT  

Early eptifibatide improves TIMI 3 patency before primary percutaneous coronary intervention for acute ST elevation myocardial infarction: results of the randomized integrilin in acute myocardial infarction (INTAMI) pilot trial
Zeymer et al.
Eur Heart J 2005;26:1971-1977.
ABSTRACT | FULL TEXT  

Pre-hospital reperfusion therapy: a strategy to improve therapeutic outcome in patients with ST-elevation myocardial infarction
Huber et al.
Eur Heart J 2005;26:2063-2074.
FULL TEXT  

The use of GP IIb/IIIa inhibitors into new perspectives: pre-catheterization laboratory administration
Beygui and Montalescot
Eur Heart J Suppl 2005;7:I10-I14.
ABSTRACT | FULL TEXT  

Facilitation of primary PCI with ReoPro: reply
Gyongyosi and Huber
Eur Heart J 2005;26:1564-1565.
FULL TEXT  

Myocardial infarction centres: the way forward
Andersen et al.
Heart 2005;91:iii12-iii15.
ABSTRACT | FULL TEXT  

Tirofiban and Sirolimus-Eluting Stent vs Abciximab and Bare-Metal Stent for Acute Myocardial Infarction: A Randomized Trial
Valgimigli et al.
JAMA 2005;293:2109-2117.
ABSTRACT | FULL TEXT  

Drug-Eluting Stents in Acute Myocardial Infarction: Is Science Catching Up With Practice?
Cohen and Ohman
JAMA 2005;293:2154-2156.
FULL TEXT  

Abciximab as Adjunctive Therapy to Reperfusion in Acute ST-Segment Elevation Myocardial Infarction: A Meta-analysis of Randomized Trials
De Luca et al.
JAMA 2005;293:1759-1765.
ABSTRACT | FULL TEXT  

Guidelines for Percutaneous Coronary Interventions: The Task Force for Percutaneous Coronary Interventions of the European Society of Cardiology
Authors/Task Force Members et al.
Eur Heart J 2005;26:804-847.
FULL TEXT  

Ageing, impaired myocardial perfusion, and mortality in patients with ST-segment elevation myocardial infarction treated by primary angioplasty
De Luca et al.
Eur Heart J 2005;26:662-666.
ABSTRACT | FULL TEXT  

Glycoprotein IIb/IIIa Inhibition
Horton
JAMA 2004;292:2211-2211.
FULL TEXT  

Glycoprotein IIb/IIIa Inhibition
Klein
JAMA 2004;292:2211-2211.
FULL TEXT  

Antiplatelet and Antithrombin Therapy for Early Management of Acute Coronary Syndromes
Wiggins and Spinler
Journal of Pharmacy Practice 2004;17:347-369.
ABSTRACT  

JournalScan
Malik
Heart 2004;90:1235-1236.
FULL TEXT  

Glycoprotein IIb/IIIa inhibition and long-term benefit: the stuff of dreams?
Montalescot
Eur Heart J 2004;25:1562-1564.
FULL TEXT